FDA approves avastin for late-stage cervical cancer
the ONA take:
Genentech, Inc. has announced that the US Food and Drug Administration (FDA) has approved Avastin (bevacizumab) for the treatment of patients with late-stage cervical cancer that is persistent, recurrent, or metastatic.
Treatment with Avastin should be in combination with paclitaxel and cisplatin or paclitaxel and topotecan. Avastin is also approved to treat patients with glioblastoma multiforme, metastatic colorectal cancer, metastatic renal cell carcinoma, and non-squamous non-small cell lung cancer. For cervical cancer, Avastin should be given at a dose of 15 mg/kg intravenously every 3 weeks.
Overall survival for patients with cervical cancer treated with chemotherapy plus Avastin had an overall survival of 16.8 months versus 12.9 months if treated with chemotherapy alone.
Avastin blocks angiogenesis and endothelial cell proliferation by binding to VEGF and preventing the interaction of VEGF to its receptors. Patients treated with Avastin should be advised to undergo routine blood pressure screenings and notified of the increased risk of wound healing complications, arterial thromboembolic events, and gastrointestinal perforation.
The National Cancer Institute estimates that at least 12,300 women in the United States will be diagnosed with cervical cancer and 4,000 will die as a result of the disease.
The FDA has approved a new use against late-stage cervical cancer.
The Food and Drug Administration has approved Genentech's Avastin for a new use against late-stage cervical cancer, the seventh indication for the blockbuster biotech drug. The FDA approved the drug late Thursday for women with cervical cancer that is persistent, recurrent or has spread to other parts of the body.
The disease is usually caused by the human papillomavirus, which is spread through sexual contact and causes cells to become cancerous. The National Cancer Institute estimates that over 12,300 U.S. women will be diagnosed with cervical cancer this year and 4,000 will die from the disease.
Sign Up for Free e-newsletters
- Association Between Multiple Myeloma With VTE and Increased Mortality at 2, 5 Years
- Advanced Concepts in Oncology Navigation
- Building a Navigation Program: A Review of the Key Components
- From Disparities to Disclosure: A Discussion on Lesbians and Breast Cancer
- Difficult Conversations: The Role of Nurse Navigator
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|